Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The study suggests hormonal factors may play a role in Frontal Fibrosing Alopecia and that treatments like oral antiandrogens and steroids could be beneficial.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

This study found that scalp hair loss is the most bothersome symptom of alopecia areata for both adults and adolescents, highlighting the need for treatments focused on improving scalp hair growth.

This study found that a 12-week supplementation with MePL, a solution of miliacin encapsulated within polar lipids, significantly reduced hair density in the telogen phase and improved scalp dryness and hair brightness in women with telogen effluvium.

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

This study strongly suggests that a distinct form of hereditary localized alopecia in a Chinese family is linked to a novel locus on chromosome 2p25.1–2p23.2.

The book is an updated guide on hair transplant techniques, useful for beginners and professionals.

Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.

In this study, baricitinib 4 mg led to greater scalp, eyebrow, and eyelash hair regrowth in severe alopecia areata patients than baricitinib 2 mg at weeks 36 and 52.

This review suggests that radiofrequency devices may be effective for both hair removal and growth, depending on the RF modality, but further research is needed to clarify their efficacy and mechanisms.

This chapter reviews trichoscopic-pathologic correlations in Frontal Fibrosing Alopecia and reports no new clinical results; the authors discuss genetics, clinical patterns, and unusual variants associated with this condition.

FUE is a minimally invasive hair transplant method using various donor sites.

A young woman developed facial bumps before hair loss, which is unusual for her condition.

This case report describes a patient with hemophagocytic lymphohistiocytosis who developed hypertrichosis and eyelash trichomegaly, likely linked to cyclosporine-A and prednisolone therapy, with expected resolution after stopping treatment.

Latanoprost eye drops caused excessive cheek hair growth and eyelash whitening in a woman.

This review explores the therapeutic applications of bimatoprost, including its role in glaucoma treatment, hair growth stimulation, and potential effects on fat deposition, but reports no new experimental findings.

In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.

This study found that oral JAK inhibitors significantly improve hair regrowth in adults with moderate-to-severe alopecia areata compared to placebo, although they are associated with a higher risk of non-serious adverse events.

This review discusses current research on cosmetic formulations, especially those involving dihydroquercetin combined with other compounds, for promoting eyelash and eyebrow growth, noting challenges with solubility and bioavailability and the potential need for further studies to validate efficacy and safety.

In this multi-center, retrospective cohort study, researchers found that tofacitinib significantly reduced SALT scores and improved eyebrow and eyelash regrowth in patients with refractory alopecia areata after 12 weeks, with greater efficacy observed in severe cases and consistent results across pediatric and adult populations.

This study found that patients with chronic, persistent alopecia areata experience significant psychosocial impairments unrelated to scalp hair loss, which influence their decision to start systemic therapy.

This retrospective case series reported that pediatric patients with alopecia totalis and subtotalis experienced significant hair regrowth after treatment with the JAK inhibitor upadacitinib, with mild acne as the most common side effect; however, larger studies are needed to establish its efficacy and safety conclusively.

This study identified potential new adverse drug reaction signals for erlotinib, used in lung and pancreatic cancer treatment, by analyzing a large dataset of case reports, indicating further clinical studies are necessary to confirm these findings.

This study reports that ritlecitinib 50 mg, with or without an initial loading dose, demonstrated meaningful and sustained efficacy up to 24 months in the Asian subpopulation with severe alopecia areata, showing significant scalp, eyebrow, and eyelash hair regrowth, along with an acceptable safety profile.

This study observed that adolescents with alopecia areata receiving ritlecitinib 50 mg daily showed notable hair regrowth over three years, as seen in both clinician- and patient-reported outcomes. However, the decreased number of participants at later stages limits the findings.

In a real-world study, baricitinib was effective for scalp, eyebrow, and eyelash regrowth in patients with alopecia areata, showing clinically meaningful improvements as early as 3 months and increasing up to 12 months; satisfaction and perceived improvement were also high among participants.

This vodcast discusses various tools for assessing the severity of alopecia areata, emphasizing the importance of considering psychosocial impacts alongside physical symptoms.

This study found that baricitinib was effective and well tolerated for long-term scalp hair regrowth in severe alopecia areata patients, with certain predictors identified for treatment response.

This report describes a rare case of eyelash overgrowth and eyelid irritation in a woman treated with erlotinib for lung adenocarcinoma, highlighting a potential side effect of the drug.

Baricitinib helps regrow hair in teens with severe alopecia areata.